Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 299

The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Open access
Kratochwil, Clemens, Fendler, Wolfgang P., Eiber, Matthias, Hofman, Michael S., Emmett, Louise, Calais, Jeremie, Osborne, Joseph R., Iravani, Amir, Koo, Phillip, Lindenberg, Liza, Baum, Richard P., Bozkurt, Murat Fani, Delgado Bolton, Roberto C., Ezziddin, Samer, Forrer, Flavio, Hicks, Rodney J., Hope, Thomas A., Kabasakal, Levent, Konijnenberg, Mark, Kopka, Klaus, Lassmann, Michael, Mottaghy, Felix M., Oyen, Wim J. G., Rahbar, Kambiz, Schoder, Heiko, Virgolini, Irene, Bodei, Lisa, Fanti, Stefano, Haberkorn, Uwe, Hermann, Ken · 2023 · European Journal of Nuclear Medicine and Molecular Imaging

Abstract

Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [177 Lu]Lu-PSMA-617 in combination with standard-of-care has been demonstrated in patients with metastatic castration-resistant prostate cancer, whose disease had progressed after or during at least one taxane regimen and at least one novel androgen-axis drug. Preliminary data suggest that 177 Lu-PSMA-radioligand therapy (RLT) also has high potential in additional clinical situations. Hence, the radiopharmaceuticals [177 Lu]Lu-PSMA-617 and [177 Lu]Lu-PSMA-I&T are currently being evaluated in ongoing phase 3 trials. The purpose of this guideline is to assist nuclear medicine personnel, to select patients with highest potential to benefit from 177 Lu-PSMA-RLT, to perform the procedure in accordance with current best practice, and to prepare for possible side effects and their clinical management. We also provide expert advice, to identify those clinical situations which may justify the off-label use of [177 Lu]Lu-PSMA-617 or other emerging ligands on an individual patient basis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00259-023-06255-8

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 113 references

Cited by

See all 299

Metadata

Authors
Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P., Lindenberg, L., Baum, R. P., Bozkurt, M. F., Delgado Bolton, R. C., Ezziddin, S., Forrer, F., Hicks, R. J., Hope, T. A., Kabasakal, L., Konijnenberg, M., Kopka, K., Lassmann, M., Mottaghy, F. M., Oyen, W. J. G., Rahbar, K., Schoder, H., Virgolini, I., Bodei, L., Fanti, S., Haberkorn, U., & Hermann, K.
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2023-05-29
Volume
50
Issue
9
Pages
2830-2845
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W4378640167
Cited by
299
References
113
FWCI
44.13
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). https://app.cochat.ai/papers/10.1007/s00259-023-06255-8
The paper
Kratochwil, C., Fendler, W. P., Eiber, M., Hofman, M. S., Emmett, L., Calais, J., Osborne, J. R., Iravani, A., Koo, P., Lindenberg, L., Baum, R. P., Bozkurt, M. F., Delgado Bolton, R. C., Ezziddin, S., Forrer, F., Hicks, R. J., Hope, T. A., Kabasakal, L., Konijnenberg, M., . . . Hermann, K. (2023). Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT). European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06255-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.